XNASDRUG
Market cap261mUSD
Dec 24, Last price
37.63USD
1D
-2.74%
1Q
3,076.33%
IPO
39.37%
Name
Bright Minds Biosciences Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-7m
L-51.46%
CFO
-7m
L-48.30%
Profile
Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑09 | 2022‑09 | 2021‑09 | 2020‑09 | 2019‑09 | |
| Income | |||||
Revenues | |||||
Cost of revenue | 7,272 | 14,738 | |||
Unusual Expense (Income) | |||||
NOPBT | (7,272) | (14,738) | |||
NOPBT Margin | |||||
Operating Taxes | 223 | ||||
Tax Rate | |||||
NOPAT | (7,272) | (14,961) | |||
Net income | (7,372) -51.46% | (15,188) 78.36% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 1,218 | 4,035 | |||
BB yield | -20.46% | -26.56% | |||
| Debt | |||||
Debt current | 74 | 68 | |||
Long-term debt | 74 | 212 | |||
Deferred revenue | |||||
Other long-term liabilities | |||||
Net debt | (6,601) | (11,348) | |||
| Cash flow | |||||
Cash from operating activities | (7,024) | (13,587) | |||
CAPEX | 5 | ||||
Cash from investing activities | |||||
Cash from financing activities | 2,190 | 5,196 | |||
FCF | (7,200) | (15,100) | |||
| Balance | |||||
Cash | 6,748 | 11,628 | |||
Long term investments | |||||
Excess cash | 6,748 | 11,628 | |||
Stockholders' equity | 5,766 | 10,543 | |||
Invested Capital | 905 | 140 | |||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 3,720 | 2,470 | |||
Price | 1.60 -73.98% | 6.15 -82.78% | |||
Market cap | 5,952 -60.83% | 15,193 -76.29% | |||
EV | (649) | 3,845 | |||
EBITDA | (7,200) | (14,732) | |||
EV/EBITDA | 0.09 | ||||
Interest | 20 | 223 | |||
Interest/NOPBT | |||||